Nautilus Biotechnology (NAUT) reported second-quarter 2026 revenue of $190,000, its first recognized revenue, including grant revenue from The Michael J. Fox Foundation and service revenue from its first Iterative Mapping Early Access Program customer.
The company reported a second-quarter net loss of $14.5 million, compared with a net loss of $15.0 million in the prior-year period. Cash, cash equivalents and investments were $129.2 million as of June 30, 2026.
- Revenue: $190,000 for the second quarter of 2026.
- Net loss: $14.5 million, compared with $15.0 million a year earlier.
- Operating expenses: $15.9 million, down 7% from $17.1 million in the prior-year period.
- Roadmap: Voyager Platform pre-orders are expected in early 2027, with instrument shipments anticipated beginning in mid-2027.
- Proteoforms: AKT1 is expected to enter the Iterative Mapping Early Access Program in late 2026.
